Quantcast
Home > Quotes > CELGZ
CELGZ

Celgene Corporation Contingent Value Rights (CELGZ) Quote & Summary Data

$0.25
*  
unch
unch
Get CELGZ Alerts
*Delayed - data as of May 21, 2018  -  Find a broker to begin trading CELGZ now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
Today's High / Low
$ 0.25 / $ 0.25
Share Volume
19,491
50 Day Avg. Daily Volume
N/A
Previous Close
$ 0.25
52 Week High / Low
$ 1.61 / $ 0.1113
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
19,491
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $0.25 is 124.62% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.25 $ 1.61
 Low: $ 0.25 $ 0.1113

Company Description (as filed with the SEC)

Celgene Corporation, together with its subsidiaries (collectively "we," "our," "us," "Celgene" or the "Company"), is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Celgene Corporation was incorporated in the State of Delaware in 1986. Our primary commercial stage products include REVLIMID®, POMALYST®/IMNOVID®, OTEZLA®, ABRAXANE®, VIDAZA®, azacitidine for injection (generic version of VIDAZA®), THALOMID® (sold as THALOMID® or Thalidomide Celgene® outside of the U.S.) and IDHIFA®. IDHIFA® was approved by the U.S.  ... More ...  

Nasdaq Official Price

Open Price:
$ 0.25
Open Date:
May 21, 2018
Close Price:
$ 0.2401
Close Date:
May 21, 2018

Research Brokers before you trade

Want to trade FX?

Analyst Info